Objective: Axial low-back pain is a disease of epidemic proportions that exerts a heavy global toll on the active workforce and results in more than half a trillion dollars in annual costs. Stem cell injections are being increasingly advertised as a restorative solution for various degenerative diseases and are becoming more affordable and attainable by the public. There have been multiple reports in the media of these injections being easily available abroad outside of clinical trials, but scientific evidence supporting them remains scarce. The authors present a case of a serious complication after a stem cell injection for back pain and provide a systematic review of the literature of the efficacy of this treatment as well as the associated risks and complications.
Methods: A systematic review of the literature was performed using the PubMed, Google Scholar, and Scopus online electronic databases to identify articles reporting stem cell injections for axial back pain in accordance with the PRISMA guidelines. The primary focus was on outcomes and complications. A case of glial hyperplasia of the roots of the cauda equina directly related to stem cell injections performed abroad is also reported.
Results: The authors identified 14 publications (including a total of 147 patients) that met the search criteria. Three of the articles presented data for the same patient population with different durations of follow-up and were thus analyzed as a single study, reducing the total number of studies to 12. In these 12 studies, follow-up periods ranged from 6 months to 6 years, with 50% having a follow-up period of 1 year or less. Most studies reported favorable outcomes, although 36% used subjective measures. There was a tendency for pain relief to wane after 6 months to 2 years, with patients seeking a surgical solution. Only 1 study was a randomized controlled trial (RCT).
Conclusions: There are still insufficient data to support stem cell injections for back pain. Additional RCTs with long-term follow-up are necessary before statements can be made regarding the efficacy and safety.
Keywords: MSC = mesenchymal stem cell; ODI = Oswestry Disability Index; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; UTSW = University of Texas Southwestern; VAS = visual analog scale; allogeneic stem cells; back pain; cauda equina syndrome; disability in the United States; global disability; lumbar; stem cell complications; stem cell injection.
Is immediate imaging important in managing low back pain?J Athl Train. 2011 Jan-Feb;46(1):99-102. doi: 10.4085/1062-6050-46.1.99. J Athl Train. 2011. PMID: 21214357 Free PMC article.
Artificial discs for lumbar and cervical degenerative disc disease -update: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(10):1-98. Epub 2006 Apr 1. Ont Health Technol Assess Ser. 2006. PMID: 23074480 Free PMC article.
Does McKenzie therapy improve outcomes for back pain?J Athl Train. 2006 Jan-Mar;41(1):117-9. J Athl Train. 2006. PMID: 16619104 Free PMC article.
Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: results at 12-months follow-up: a systematic review of the literature.Arch Orthop Trauma Surg. 2019 Aug 27. doi: 10.1007/s00402-019-03267-8. Online ahead of print. Arch Orthop Trauma Surg. 2019. PMID: 31456015 Review.
Palliative Treatment of Cancer-Related Pain [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 09-2005. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH). 2005. PMID: 29320015 Free Books & Documents. Review.